


Point-of-Delivery Reconstitution Systems

Devices, Therapeutics, Strategies and Prospects



Greystone Associates is pleased to announce the publication of a new market study. **Point-of-Delivery Reconstitution Systems: Devices, Therapeutics, Strategies and Prospects** is a comprehensive evaluation and analysis of the technology, devices and participants behind the innovative approaches that address the growing need for packaging and delivering lyophilized drugs for injection.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for reconstituting lyophilized drugs at the point of use. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Innovative Devices and the Growth of Biological Drugs

The inherent instability of biological drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed – a distribution strategy referred to as the ‘Cold Chain’. Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins must be reconstituted prior to injection. Lyophilized drugs are sold with reconstitution vial systems, or packaged in special injection devices (e.g., pens, needle-free injectors, two-part syringes) that allow reconstitution to take place in the device prior to injection. As biological drugs continue to grow in terms of therapeutics and total prescriptions, the impact of specialty devices will increase.

Report Value Matrix




Table of Contents

Executive Summary

Market Dynamics

- Prolonging the Shelf Life of Biological Drugs
 - Distribution Strategies
 - Formulation Strategies
- Lyophilization and Reconstitution at the Point of Use
- The Economics of Reconstitution Systems
- What's Driving the Growth in Engineered Reconstitution Systems?
 - Biological Drugs Proliferating
 - The Trend toward Self-Administration
 - Shifting Demographics
 - Innovation in Disposable Device Designs
- Therapeutic Demand Drivers
- Competitive Landscape
- Risk Factors

Drug Reconstitution Systems – Commercial Devices

- Vial Adapters
- Vial-to-Vial Systems
- Needle-less Transfer Devices
- Direct Connect to Vial
- Dual Chamber Syringes
- Single Chamber Syringes

Reconstitution System Design Factors

- Stability and Material Selection Issues
- Disposable Drug Cartridges
- Single vs Multi-Dose Devices
- Human Engineering/Ergonomics

Drug Reconstitution - User Segment Analysis

- Self-Administration
- Healthcare Provider/Care-giver
- Acute Care Facilities
- Chronic/Long-term Facilities
- Public Health

Drug Reconstitution - Therapeutic Sector Analysis

- Antibiotics/Antivirals
- Monoclonal Antibodies
- Autoimmune Diseases
- Hepatitis
- Hematopoietics
- Hormone Replacement

- Osteoporosis
- Reproductive Health
- Vaccines

Market Factors

- Syringe Disposal
- Regulatory Issues
- Patient Compliance
- Healthcare Economics

Drug Reconstitution Systems- Company Profiles

Feature Summary

- Provides detailed analysis of injectable lyophilized drugs and assess key market segments, market dynamics and market demographics
- Analyzes therapeutic demand drivers and evaluates the market impact and potential of commercial reconstitution systems
- Analyzes design factors, material selection issues, technologies and market development issues
- Charts data, market share, and forecasts to 2012
- Profiles reconstitution system suppliers, their product activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of pharma-device alliances and design partnerships on reconstitution systems
- Evaluates the impact of economic, technology, and regulatory factors

Report Format and Availability

This report is available electronic format. A site license for a single physical location and an Enterprise license are also available.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address. Orders which are not prepaid must indicate the billing address. There is no charge for handling and shipping for destination addresses within the continental US.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Wire Transfers: See 'Wire Transfers' below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer. There is a \$50 per copy shipping and handling charge for international shipments.

Wire Transfers: TD Banknorth
300 Franklin Street
Manchester, NH 03103
(Call for Account Information)

Mailing Address: Greystone Associates
Client Services
P.O. Box 1362
Amherst, NH 03031

Point-of-Delivery Reconstitution Systems: Devices, Therapeutics, Strategies & Prospects

Select	Format	Price (U.S. funds)	Total
<input type="checkbox"/>	Electronic	\$2,850.00	
<input type="checkbox"/>	Site License	\$3,850.00	
<input type="checkbox"/>	Enterprise License	\$5,500.00	
Total Payment (U.S. funds)			

Method of Payment: Company Check    Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ Card CVV _____ Signature _____

Billing Information	Shipping Information
Name:	<input type="checkbox"/> Click here if same as Billing Information Name:
Title:	Title:
Company:	Company:
Street Address:	Street Address:
City,State/Province:	City,State/Province:
Country/Postal Code:	Country/Postal Code:
Phone:	Phone:
Fax:	Fax:
Email:	Email: